Explore 3 Stock Ideas & Industry Insights Download Free Report

Avricore Health Inc

Company price
0.0008 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
6000
Market Cap
0.10M

Momentum Score

…

Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.04
High
52 Week Price Range
0.00
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avricore Health Inc is a small publicly listed company with limited public disclosure that appears to operate in the diagnostics and health-services sector. Long-term growth drivers may include rising demand for decentralized testing, aging populations, and broader adoption of digital-health delivery, which could support companies offering diagnostic capabilities. Investors may find exposure to secular healthcare trends and any operational progress reported by the company attractive.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.19M
Revenue Per Share
0.00
Gross Profit TTM
-0.07M
Debt / Equity
0.02
ROE
-132.03%
Net Debt
-0.23M
ROCE
-351.04%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.86M -0.67M -0.70M -1.71M -1.71M
Net income -1.86M -0.67M -0.70M -1.75M -1.75M
Selling general administrative 1.32M 1.75M 1.84M 1.71M 1.71M
Selling and marketing expenses - - 0.00M 0.18M -
Gross profit 0.24M 1.88M 1.20M 0.03M 0.03M
Reconciled depreciation 0.14M 0.45M 0.37M 0.18M 0.02M
Ebit -1.37M 0.18M -0.70M -1.75M -1.75M
Ebitda -1.23M 0.63M -0.28M -1.73M -1.73M
Depreciation and amortization 0.14M 0.45M 0.42M 0.02M 0.02M
Operating income -1.37M 0.18M -0.69M -1.75M -1.75M
Other operating expenses 1.90M 4.66M 4.17M 1.86M 1.86M
Interest expense 0.01M - 0.00M 0.04M 0.04M
Interest income 0.01M 0.00M 0.00M 0.01M 0.00M
Net interest income 0.00M 0.00M -0.00M 0.00M -0.04M
Income tax expense - - 0.00M 0.04M 0.04M
Total revenue 0.53M 4.79M 3.49M 0.12M 0.12M
Total operating expenses 1.60M 1.75M 1.89M 1.77M 1.77M
Cost of revenue 0.30M 2.91M 2.28M 0.09M 0.09M
Total other income expense net -0.49M -0.85M -0.01M 0.04M 0.04M
Net income from continuing ops -1.86M -0.67M -1.01M -0.82M -1.71M
Net income applicable to common shares - - - - -1.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.56M 2.30M 2.54M 2.28M 2.28M
Intangible assets 0.00M 0.06M 0.05M 0.03M 0.03M
Other current assets 0.09M 0.02M 0.05M - 0.05M
Total liab 0.17M 0.33M 0.53M 0.08M 0.08M
Total stockholder equity 0.39M 1.97M 2.01M 2.20M 2.20M
Other current liab 0.00M - 0.10M 0.05M -
Common stock 27.28M 27.30M 27.19M 26.62M 26.62M
Capital stock 27.30M 27.30M 27.19M 27.06M 26.62M
Retained earnings -34.24M -32.40M -31.74M -30.22M -30.22M
Cash 0.23M 1.13M 0.28M 2.01M 2.01M
Total current liabilities 0.17M 0.33M 0.53M 0.08M 0.08M
Current deferred revenue - - -0.04M 0.25M -
Net debt -0.23M -1.13M -0.24M -1.97M -1.97M
Short term debt - - 0.04M 0.04M 0.04M
Short long term debt - - 0.04M 0.04M 0.04M
Short long term debt total - - 0.04M 0.04M 0.04M
Other stockholder equity - 7.07M -0.00M - 5.79M
Property plant equipment - - - - 0.09M
Total current assets 0.37M 1.58M 0.77M 2.16M 2.16M
Net tangible assets - - - - 2.17M
Short term investments 0.01M 0.01M 0.01M 0.01M -
Net receivables 0.04M 0.42M 0.42M 0.09M 0.09M
Inventory 0.00M 0.00M 0.02M - -
Accounts payable 0.17M 0.26M 0.43M 0.04M 0.04M
Accumulated other comprehensive income 7.34M -0.00M 6.56M 5.79M 5.79M
Non current assets total 0.20M 0.72M 1.76M 0.12M 0.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.21M -1.13M -1.21M -0.14M
Change to liabilities - - - - -0.07M
Total cashflows from investing activities -0.11M -0.21M -1.05M - -0.14M
Net borrowings 0.00M -0.03M 0.00M - -1.00M
Total cash from financing activities 0.00M 0.06M 0.04M 3.08M 3.08M
Change to operating activities - - - - 0.07M
Net income -1.86M -0.67M -0.70M -1.71M -1.71M
Change in cash -0.85M 0.86M -0.34M 1.71M 1.71M
Begin period cash flow 1.08M 0.28M 0.62M 0.30M 0.30M
End period cash flow 0.23M 1.13M 0.28M 2.01M 2.01M
Total cash from operating activities -0.79M 1.00M 0.66M -1.23M -1.23M
Issuance of capital stock - - 0.00M 0.00M 2.40M
Depreciation 0.14M 0.45M 0.42M 0.02M 0.02M
Other cashflows from investing activities - -0.02M -0.03M - -
Change to inventory 0.00M 0.02M -0.02M 0.00M 0.00M
Change to account receivables 0.39M 0.01M 0.34M -0.08M -0.08M
Other cashflows from financing activities - 0.09M 0.04M 1.68M 1.68M
Change to netincome - - - - 0.53M
Capital expenditures 0.09M 0.21M 1.05M 0.14M 0.14M
Change in working capital 0.16M -0.11M 0.23M -0.08M -0.08M
Stock based compensation 0.28M 0.54M 0.70M 0.50M 0.50M
Other non cash items 0.49M 0.79M 0.00M 0.04M 0.04M
Free cash flow -0.88M 0.80M -0.39M -1.37M -1.37M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVCRF
Avricore Health Inc
-
-%
0.00 - - 0.52 0.72 51.14 41.13
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Avricore Health Inc

Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

700 ? 1199 West Hastings Street, Vancouver, BC, Canada, V6E 3T5

778 968 1176

Name Title Year Born
Mr. Hector Bremner CEO & Director 1982
Ms. Kiriaki Smith CPA, CFO, CGA, CPA CFO & Corp. Sec. 1967
Mr. Rodger Seccombe Head of Healthtab Division & Director 1981
Mr. Will Seccombe Communications Advisor NA
Dr. Allan Shapiro Mang. of Bus. Devel. NA
Ms. Kiriaki Smith CPA, CFO, CGA, CPA CFO & Corporate Secretary 1967
Mr. Rodger Seccombe CTO & Director 1981
Mr. Rodger Seccombe CEO, CTO & Director 1981
Ms. Kiriaki Smith CPA, CFO, CGA CFO & Corporate Secretary 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…